Investment Thesis

would necessitate close monitoring of competitive pressures and regulatory developments.

Competitive Moat

Stryker boasts a strong intangible asset moat, characterized by a well-established brand reputation and an extensive portfolio of patented medical technologies. The company's products, particularly in orthopedics and neurotechnology, are essential to healthcare providers, resulting in significant switching costs for customers. This competitive advantage is durable over the next 5-10 years, driven by continuous innovation and regulatory barriers to entry. Key threats include emerging competitors in the orthopedic space and potential disruptive technologies that could alter surgical practices.

Growth Engine

Future revenue growth for Stryker is anticipated to stem from several key areas. The total addressable market (TAM) for orthopedic and neurotechnology products is projected to grow at an annual rate of 5-7%, fueled by an aging population and increasing demand for surgical interventions. Stryker is effectively leveraging its R&D capabilities to launch innovative products, while also considering strategic acquisitions to bolster its market presence. The company is gaining market share, indicated by recent sales growth in its MedSurg and Neurotechnology segments, which outpaced industry averages.